$ATYRSep 1, 2026, 8:36 PMAI processed
aTyr expects mid-September FDA reply on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
AI Summary
ATyr (ATYR) says it anticipates an FDA response by mid-September 2026 to the protocol submitted in June for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The proposed global, randomized, double-blind, placebo-controlled 54-week trial would enroll up to ~372 patients, randomize 1:1 to 5.0 mg/kg IV efzofitimod or placebo every 3 weeks (17 doses), and use change in FVC at week 48 as the primary endpoint with King's Sarcoidosis Questionnaire‑Lung score as a key secondary.
Positives
- Company expects an FDA response by mid-September 2026 — a near-term regulatory catalyst
- Planned Phase 3 has a clear registrational design: randomized, double-blind, placebo-controlled, 54 weeks, up to ~372 patients
- Primary endpoint is change in FVC at week 48 with KSQ‑Lung as a key secondary (objective lung function + patient-reported outcome)
Negatives
- Timing is an anticipated FDA response, not guaranteed; review could be delayed or require changes
- Enrollment limited to patients on stable ≤5 mg/day oral corticosteroid and/or background immunosuppressant, which may narrow eligible population
- Efzofitimod remains investigational with no Phase 3 efficacy/safety data yet